- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | Nasdaq Stockholm AB: New equity right for trading, Biosergen AB TO3 | 126 | GlobeNewswire | At the request of Biosergen AB, Biosergen AB equity rights will be traded on
First North Growth Market as from April 24, 2024.
Security name: Biosergen AB TO3
--------------------------------
Short... ► Artikel lesen | |
| 17.04. | Nasdaq Stockholm AB: Last day of trading in paid subscription units (BTU) of Biosergen AB | 133 | GlobeNewswire | Trading in Biosergen AB paid subscription units is to cease. The last trading
day is April 18, 2024.
Short name: BIOSGN BTU
ISIN code: SE0021628583
Orderbook ID: 326203
This information is... ► Artikel lesen | |
| 16.04. | BIOSERGEN AB: Conversion of paid subscribed units and first day of trading with warrants of series TO3 | 1 | Cision News | ||
| 09.04. | BIOSERGEN AB: Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue | 1 | Cision News | ||
| 26.03. | BIOSERGEN AB: Biosergen announces the outcome in the rights issue | 2 | Cision News | ||
| 18.03. | BIOSERGEN AB: BioStock Investor Pitch: Biosergen | 1 | Cision News | ||
| 15.03. | BIOSERGEN AB: Members of the board of directors and management subscribe in ongoing rights issue | 1 | Cision News | ||
| 08.03. | BIOSERGEN AB: Biosergen attacks invisible threat of fungal infections | 1 | Cision News | ||
| 06.03. | Nasdaq Stockholm AB: Listing of unit right of Biosergen AB (116/24) | 197 | GlobeNewswire | With effect from March 07, 2024, the unitright in Biosergen AB will be traded
on First North Growth Market. Trading will continue up until and including
March 18, 2024.
Instrument: Subscription... ► Artikel lesen | |
| 01.03. | Bulletin from the extraordinary general meeting in Biosergen AB (publ) | 1 | Cision News | ||
| 01.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.03.2024 | 395 | Xetra Newsboard | Das Instrument AYH FR001400KO61 ARCHOS S.A. NOM. EO 0,055 EQUITY wird cum Kapitalmassnahme gehandelt am 01.03.2024 und ex Kapitalmassnahme am 04.03.2024 The instrument AYH FR001400KO61 ARCHOS S.A. NOM.... ► Artikel lesen | |
| 29.02. | Biosergen AB: Biosergen publishes interim report for fourth quarter 2023 | 138 | GlobeNewswire (Europe) | Thursday, February 29, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the fourth quarter 2023. The interim report is available as an attached document and... ► Artikel lesen | |
| 12.02. | BIOSERGEN AB: Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection. | 1 | Cision News | ||
| 30.01. | Notice of Extraordinary general meeting in Biosergen AB | 2 | Cision News | ||
| 30.01. | BIOSERGEN AB: Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan | 1 | Cision News | ||
| 12.01. | Biosergen AB: Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor | 32 | GlobeNewswire (Europe) | Stockholm, Sweden - January 12, 2024 - Biosergen AB ("Biosergen" or the "Company"), a clinical-stage biotech company specializing in the development of innovative antifungal therapies, today announced... ► Artikel lesen | |
| 12.12.23 | BIOSERGEN AB: Biosergen's Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy | 1 | Cision News | ||
| 30.11.23 | BIOSERGEN AB: Biosergen publishes interim report for third quarter 2023 | 1 | Cision News |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,940 | +0,90 % | Qiagen: Leicht enttäuschend | Der Labordienstleister und Diagnostikspezialist Qiagen rechnet in einem herausfordernden Umfeld mit einer Stabilisierung seiner Geschäfte. Bei konstanten Wechselkursen soll der Konzernumsatz des zweiten... ► Artikel lesen | |
| EVOTEC | 9,760 | -1,36 % | Bayer und Evotec schließen Vereinbarung | Bayer und das deutsche Life-Science-Unternehmen Evotec haben heute bekannt gegeben, dass sie den Schwerpunkt ihrer strategischen Zusammenarbeit auf die Entwicklung innovativer Präzisionsbehandlungen... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,110 | +4,06 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 37,400 | +3,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,000 | -6,98 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,080 | +0,31 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| NUVALENT | 70,35 | -2,95 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| CG ONCOLOGY | 36,270 | -8,18 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| JANUX THERAPEUTICS | 64,78 | +3,76 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| ANNEXON | 4,880 | +4,72 % | Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? | ||
| SANA BIOTECHNOLOGY | 10,440 | +6,75 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
| CABALETTA BIO | 12,390 | -1,67 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 26,450 | +3,40 % | Navigating 7 Analyst Ratings For Avidity Biosciences |
Das Unternehmen BIOSERGEN AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,026 Euro und damit +1,56 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
